Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia
2024
New Drug for Vascular Cognitive Impairment and Dementia
Sample size: 3
publication
Evidence: moderate
Author Information
Author(s): Akif Adnan, Nguyen Thi Thanh My, Liu Langni, Xu Xiaotian, Kulkarni Amol, Jiang Jianxiong, Zhang Yang, Hao Jiukuan
Hypothesis
Can a novel sulfonylurea compound effectively target NLRP3 signaling to treat vascular cognitive impairment and dementia?
Conclusion
AMS-17 shows promise in improving cognitive function and reducing neuroinflammation in a mouse model of vascular cognitive impairment and dementia.
Supporting Evidence
- AMS-17 treatment improved cognitive function in VaD mice.
- The drug enhanced blood-brain barrier integrity.
- AMS-17 promoted remyelination in the brain.
- Neurodegeneration was reduced with AMS-17 treatment.
- The expression of NLRP3 and associated proteins decreased.
- Pro-inflammatory cytokines TNF-α and IL-1β levels were lowered.
- Anti-inflammatory IL-4 levels increased in the blood.
Takeaway
A new drug called AMS-17 helps mice with memory problems by making their brains healthier and reducing inflammation.
Methodology
The study used a VaD mouse model and assessed cognitive function through various tests while analyzing brain and blood samples.
Participant Demographics
Mice were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website